Wild-type EGFR disruption suppressed HER2/HER3 expression, but mutant EGFR loss or TKI resistance increased HER2/HER3 expression, promoting tumor cell survival and drug resistance via cyclin D1. Here, ERBB2 is linked to neoplasm.